Swiss Medica Inc., Innovative Products That Improve Peoples' Lives

5/5/2005 1:46:56 PM ET

SWISS MEDICA ISSUES STORE COUNT GUIDANCE FOR O24™ PAIN NEUTRALIZER PRODUCT

FOR IMMEDIATE RELEASE

Stock Symbol: OTC BB: SWME

May 5, 2005

SWISS MEDICA ISSUES STORE COUNT GUIDANCE FOR O24™ PAIN NEUTRALIZER PRODUCT

Toronto, Canada – Swiss Medica, Inc. (OTC BB: SWME) is pleased to announce its projection of the number of

retail stores that will be stocking its O24™ Pain Neutralizer product through the end of 2005. Retail distribution in

the United States and Canada currently stands at more than 6,000 stores.

“We anticipate increasing U.S. and Canadian retail distribution for our O24™ Pain Neutralizer to more than

13,000 stores by the end of Q2, increasing to 19,000 stores by Q3 and 25,000 stores by the end of 2005,”

announced Tom Quinn, Swiss Medica’s Executive Vice President.

About Swiss Medica Inc.

Swiss Medica commercializes proprietary bioscience products that relieve chronic ailments. We increase our

market share through focused distribution strategies in multiple sales channels. Swiss Medica's mission is to be a

world leader in the commercialization of life enhancing bioscience products that improve quality of lives. Please

visit our websites at www.swissmedica.com and

Swiss Medica's flagship product, the O24™ Pain Neutralizer, holds US Patent #6,444,238B1. The O24™ pain

relief solution has been used, recommended and praised for its fast-acting and long-lasting benefits by

healthcare professionals in the United States, Canada and in Europe. O24™ is widely available throughout

Canada in leading pharmacies and natural food stores. It is currently sold in an increasing number of

pharmacies throughout the United States. Customers can also visit

, for ordering details and

store locators for the nearest pharmacy.

Forward-looking statements in this news release are made pursuant to the "Safe Harbor" provisions of the United

States Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking

statements involve risks and uncertainties, including, without limitation, risks relating to the ability to close

transactions being contemplated, risks related to international sales and potential foreign currency exchange

fluctuations, continued acceptance of Swiss Medica's products, increased levels of competition, technological

changes, dependence on intellectual property rights and other risks detailed from time to time in Swiss Medica's

periodic reports filed with the United States Securities and Exchange Commission and other regulatory

authorities.

For more information, please contact:

Swiss Medica Inc.

Investor Relations Contact:

David Jones

(866) 485-4243